WHO vaccine-preventable diseases: monitoring system. 2013 global summary

Last updated 20-Octl-2013 (data as of 16-Oct-2013)
Next overall update June 2014
EPI mother and child logo         
Select a country

Development status: Least developed GNI / capita (US$): 3'6701 Infant (under 12 months) mortality rate: 462
GDP / capita (US$): 1'7091 Child (under 5 years) mortality rate: 542

Population data in thousands3

  2012  2011  2010  2009  2008  2000  1990  1980 
Total population 1'114  1'096  1'079  1'064  1'050  854  751  581 
Births 40  40  39  39  39  38  33  23 
Surviving infants 39  38  38  37  37  35  28  18 
Pop. less than 5 years 190  188  181  177  172  174  124  76 
Pop. less than 15 years 518  516  511  508  502  425  298  231 
Female 15-49 years 234  228  223  219  215  168  191  151 

Number of reported case

(Click for retrospective incidence data for Timor-Leste)
Diphtheria
Japanese encephalitis
Measles 16  763  50  10 
Mumps
Pertussis
Polio*
Rubella
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total) 10 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Timor-Leste)
Vaccine year result method % card seen                                                
BCG 2008  77  DHS   49.6  71  68  71  71  85 
DTP1 2008  75  DHS   49.6  82  69  75  76  85 
DTP3 2008  66  DHS   49.6  83  67  72  72  79 
HepB_BD         
HepB3 2008  66  DHS   49.6  83  67  72  72  79 
Hib3         
JapEnc         
MCV 2008  68  DHS   49.6  73  62  66  70  73 
MCV2         
PCV1         
PCV3         
Pol3 2008  56  DHS   49.6  83  66  72  78  79 
Rota1         
Rota_last         
Rubella1         
TT2plus 2004  60  EPI   26.0  39  38  33  39  58 
PAB         
VAD1          57  39  51  84  29 
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2014

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Timor-Leste)
BCG 71  68  71  71  85 
DTP1 69  69  75  76  85 
DTP3 67  67  72  72  79 
HepB3 67  67  72  72  79 
Hib3
MCV 62  62  66  70  73 
PAB 81  81  81  81  66 
PCV3
Pol3 66  66  72  78  79 
Rota_last

Number of districts in the country 13  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
99 
   
/
|
|
\
Greater or equal to 90% 15
From 80 to 89% 38
From 50 to 79% 46
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2012 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth- 1 year; Yes
DTwPHep 6, 10, 14 weeks; Yes
DTwPHibHepB 6, 10, 14 weeks; Yes
Measles 9 months; Yes
OPV Birth- 2 weeks; 6, 10, 14 weeks; Yes
TT 1st contact pregnancy; +1, +6 months; +1, +1 year; Yes
VitaminA 6, 12, 18, 24, 30, 36 months; Yes

Immunizaton indicators

Indicator Expected answer 2012  2011  2010  2009  2008  2007  2006 

Planning and management

Multi-year plan (MYP) for immunization Yes/No/NR Yes  Yes  Yes  Yes  No  No  No 
What years does the MYP cover? number 2009-2013  2009-2013    2009-2013      NA 
Nº of districts with microplans that include activities to raise immunization coverage number 10  13      13 

National Immunization Advisory Mechanism

Does the country have a standing technical advisory group on immunization? Yes/No/NR No  No  No         

System performance

Total number of districts in country number 13  13  13  13  13  13  13 
Nº districts with DTP3 coverage >=80% number
% of districts with DTP3 coverage >=80% From 0 to 100% 54  15  23  46  46  38  23 
Nº districts with measles (MCV1) coverage >=95% number    
% of districts with MCV1 coverage >=95% From 0 to 100% 15  15  15     

Safety

Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NR Yes  Yes  No  Yes  No  No  No 
Does your country have a vaccine adverse events review committee? Yes/No/NR/ND No  No  No         

Finance

Percentage of routine vaccines funded by Government From 0 to 100% 26  100  100  100     

Maternal and neonatal tetanus (NT) elimination

NT eliminated Yes/No Yes  No  No  No  No  No  No 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2012, data for 2011
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.